Cargando…
Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment
AIMS: Fluocinolone acetonide (FAc) is an intravitreal corticosteroid implant approved for the second-line treatment of diabetic macular edema (DME). This study compared outcomes of patients with DME switched directly to an FAc implant, versus indirectly via dexamethasone, after anti-VEGF therapy fai...
Autores principales: | Rehak, Matus, Busch, Catharina, Unterlauft, Jan-Darius, Jochmann, Claudia, Wiedemann, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093402/ https://www.ncbi.nlm.nih.gov/pubmed/31749051 http://dx.doi.org/10.1007/s00592-019-01439-x |
Ejemplares similares
-
Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
por: Baillif, Stéphanie, et al.
Publicado: (2022) -
Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
por: Messenger, Wyatt B, et al.
Publicado: (2013) -
General health of patients with diabetic macular edema—The LIPSIA study
por: Busch, Catharina, et al.
Publicado: (2021) -
Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries
por: Lebrize, Sarah, et al.
Publicado: (2022) -
Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant
por: Bertelmann, Thomas, et al.
Publicado: (2015)